Breakthrough therapeutic optimization platform combining enhanced salsalate nanoformulations with real-time biomarker-guided AI systems
Revolutionary nanotechnology platform delivering targeted joint pain relief, cartilage protection, and disease modification for comprehensive osteoarthritis management
Advanced nanotechnology platform delivering superior pre-operative and post-operative pain relief with enhanced recovery protocols and reduced opioid dependency
Revolutionary nanotechnology platform for traumatic brain injury, dementia, Alzheimer's disease, and neuroinflammatory conditions with neuroprotective salsalate formulations
Advanced nanotechnology platform delivering superior pain relief for acute conditions, chronic pain, and osteoarthritis with enhanced safety and efficacy
Advanced AI-driven multi-agent optimization system with enhanced nanoformulated therapeutics
Machine learning algorithms analyze patient biomarkers in real-time to optimize therapeutic selection and dosing for personalized CRS management.
Proprietary nanoformulated salsalate with 10x enhanced bioavailability, enabling effective IV administration for severe CRS cases.
Continuous monitoring of IL-6, IL-1β, and other inflammatory markers with automated treatment adjustments based on patient response.
Simultaneous optimization of tocilizumab, anakinra, corticosteroids, and other CRS therapeutics for maximum efficacy and safety.
Early intervention triggers and outcome prediction models to prevent severe CRS complications before they occur.
$200M+ patent portfolio covering system, method, and composition claims with global protection strategy.
Strategic roadmap from proof-of-concept to global commercialization
Complete AI algorithm validation and Nanotrol™ formulation optimization with initial efficacy studies.
Investigational New Drug application with comprehensive preclinical package and manufacturing plans.
First-in-human safety and dosing study with 40 CAR-T patients at leading cancer centers.
Pivotal efficacy trial demonstrating 85% reduction in severe CRS events with 200 patients.
FDA approval followed by global regulatory submissions and commercial launch preparation.
Join us in revolutionizing CAR-T therapy with breakthrough CRS management technology
Comprehensive pitch deck with detailed financials, market analysis, and investment terms
22 slides covering technology, market, financials, and investment opportunity
View Full Presentation